Corient Private Wealth LP Reduces Stake in United Therapeutics Corporation $UTHR

Key Points

• Corient Private Wealth reduced its United Therapeutics stake by 35.9% in the second quarter, selling 7,513 shares and retaining 13,429 shares valued at approximately $7.28 million.
• United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
• Analysts maintain a generally positive outlook, with an average “Moderate Buy” rating and a $646 price target, although insiders—including CEO Martine Rothblatt—have sold shares recently.

Corient Private Wealth LP reduced its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 35.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,429 shares of the biotechnology company's stock after selling 7,513 shares during the quarter. Corient Private Wealth LP's holdings in United Therapeutics were worth $7,276,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Arjuna Capital raised its holdings in United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after purchasing an additional 18 shares in the last quarter. Sage Rhino Capital LLC boosted its stake in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock valued at $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC increased its position in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after buying an additional 24 shares during the period. Meeder Advisory Services Inc. increased its position in shares of United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after buying an additional 26 shares during the period. Finally, Kera Capital Partners Inc. raised its stake in United Therapeutics by 6.1% in the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company's stock worth $279,000 after buying an additional 27 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $497.27 on Friday. The company has a market cap of $21.33 billion, a P/E ratio of 17.79, a PEG ratio of 2.50 and a beta of 0.56. United Therapeutics Corporation has a 1 year low of $402.50 and a 1 year high of $609.35. The stock's fifty day moving average price is $516.53 and its 200-day moving average price is $540.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the company earned $6.41 EPS. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, July 10th. The stock was sold at an average price of $544.60, for a total transaction of $5,173,700.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,063,379.80. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 356,003 shares of company stock valued at $186,182,652. 8.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

UTHR has been the subject of a number of research analyst reports. Morgan Stanley set a $515.00 target price on United Therapeutics in a research note on Thursday, August 6th. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Finally, Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $646.00.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.